Genmab is now worth more than Lundbeck
With just one marketed drug in its portfolio, Danish biotech company Genmab has raised its market cap to DKK 3 billion above that of Lundbeck, which commands a portfolio of 12 drugs.
BY BENJAMIN WERNER CHRISTENSEN
Genmab’s clinical pipeline is more interesting than all of Lundbeck’s approved drugs and candidates in its clinical pipeline combined. That’s is roughly how the markets values the two companies.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Increased belief in Genmab’s potential blockbuster
For abonnenter
"I haven’t spoken to anyone myself"
For abonnenter
